Table 1. Prevalence of surveillance drug resistance mutations (SDRM) amongst HIV-1 infected individuals throughout South Africa.
| Province | Patients on ART (%) | Assigned samples (n) | Available sequences (n) | Any SDRM (n) | Any SDRM (%) | Any SDRM (95% CI) | NNRTI SDRM (n) | NNRTI SDRM (%) | NNRTI SDRM (95% CI) | NRTI SDRM (n) | NRTI SDRM (%) | NRTI SDRM (95% CI) | PI SDRM(n) | PI SDRM(%) | PI SDRM(95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eastern Cape | 7.8 | 26 | 25 | 4 | 16.0 | 5.8–35.3 | 4 | 16.0 | 5.8–35.3 | 1 | 4.0 | 0.0–21.1 | 0 | 0.0 | 0.0–15.8 |
| Free State* | 7.6 | 25 | 25 | 3 | 12.0 | 3.3-30-8 | 3 | 12.0 | 3.3-30-8 | 1 | 4.0 | 0.0–21.1 | 0 | 0.0 | 0.0–15.8 |
| Gauteng | 15.8 | 53 | 47 | 3 | 6.4 | 1.6–17.8 | 3 | 6.4 | 1.6–17.8 | 1 | 2.1 | 0.0–12.1 | 0 | 0.0 | 0.0–9.0 |
| KwaZulu-Natal** | 38.3 | 129 | 121 | 11 | 9.1 | 5.0–15.7 | 10 | 8.3 | 4.4–14.7 | 3 | 2.5 | 0.5–7.4 | 1 | 0.8 | 0.0–5.0 |
| Limpopo | 4.7 | 16 | 13 | 1 | 7.7 | 0.0–35.4 | 1 | 7.7 | 0.0-35-4 | 0 | 0.0 | 0.0–26.6 | 0 | 0.0 | 0.0–26.6 |
| Mpumalanga* | 8.1 | 27 | 27 | 2 | 7.4 | 1.0–24.5 | 1 | 3.7 | 0.0–19.8 | 1 | 3.7 | 0.0–19.8 | 1 | 3.7 | 0.0–19.8 |
| North West | 10.6 | 36 | 13 | 1 | 7.7 | 0.0–35.4 | 1 | 7.7 | 0.0–35.4 | 0 | 0.0 | 0.0–26.6 | 0 | 0.0 | 0.0–26.6 |
| Northern Cape | 0.4 | 1 | 1 | 0 | 0.0 | 0.0–83.3 | 0 | 0.0 | 0.0–83.3 | 0 | 0.0 | 0.0–83.3 | 0 | 0.0 | 0.0–83.3 |
| Western Cape | 6.7 | 23 | 5 | 0 | 0.0 | 0.0–48.9 | 0 | 0.0 | 0.0–48.9 | 0 | 0.0 | 0.0–48.9 | 0 | 0.0 | 0.0–48.9 |
| TOTAL | 100.0 | 336 | 277 | 25 | 9.0 | 6.1–13.0 | 23 | 8.3 | 5.6–12.2 | 7 | 2.5 | 1.1–5.2 | 2 | 0.7 | 0.0–2.8 |
* 1 sample with ≥ 4 mutations
** 2 samples with ≥ 4 mutations